Compare Delta Air Lines, Inc. (DAL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs TG Therapeutics Inc — how do they compare? Delta Air Lines, Inc. trades at $89.86 (market cap $59.46B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Delta Air Lines, Inc. is far larger — about 7.8× TG Therapeutics Inc's market cap, and Delta Air Lines, Inc. pays a 0.86% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DAL | TGTX | |
|---|---|---|
Market Cap | $59.46B | $7.64B |
Sector | Industrials | Health |
52-Week High | $93.66 | $59.06 |
52-Week Low | $55.65 | $26.94 |
Enterprise Value | $74.77B | $7.84B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $90.14, up 1.04% on the day, with strong technical momentum and consistent earnings beats. The stock shows bullish moving average signals and trades near pivot point resistance at $91. Fundamentally, DAL reported Q2 2026 EPS of $1.56, beating estimates, with revenue growth to $63.36B in 2025 and a net margin of 5.78%. The company maintains robust cash flow from operations of $8.34B and a declining debt-to-asset ratio of 17.35% in 2025.
Outlook remains positive with an 81.82% analyst buy rating and a $108.27 consensus price target, implying 20% upside. Key risks include fuel cost volatility and competitive pressure, but DAL's premium travel demand and loyalty program strength support growth. Institutional sentiment is favorable despite recent insider sales, with net cash flow positive at $1.08B in 2025.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
